Cannabinoid CB<sub>2</sub> receptor ligand profiling reveals biased signalling and off-target activity.

Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N, Finlay D, MacDonald C, Chicca A, Gens MD, Stuart J, de Vries H, Mastrangelo N, Xia L, Alachouzos G, Baggelaar MP, Martella A, Mock ED, Deng H, Heitman LH, Connor M, Di Marzo V, Gertsch J, Lichtman AH, Maccarrone M, Pacher P, Glass M, van der Stelt M. · 2017

Read Cannabinoid CB<sub>2</sub> receptor ligand profiling reveals biased signalling and off-target activity. by Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N, Finlay D, MacDonald C, Chicca A, Gens MD, Stuart J, de Vries H, Mastrangelo N, Xia L, Alachouzos G, Baggelaar MP, Martella A, Mock ED, Deng H, Heitman LH, Connor M, Di Marzo V, Gertsch J, Lichtman AH, Maccarrone M, Pacher P, Glass M, van der Stelt M. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5216056.txt.

Introduction

Marjolein Soethoudt and a large multi-laboratory team profiled ligands of the cannabinoid CB2 receptor in Nature Communications in 2017. The CB2 receptor is a promising drug target for tissue injury and inflammatory disease. Yet the many compounds used to activate it in research had been poorly checked for selectivity and side actions.

Working across academic and industry labs, the team compared the most widely used CB2 compounds. They measured how each activates distinct signaling routes inside cells, a pattern called biased signaling, and how often they hit other targets. Some popular agonists differed sharply from others on both counts. The group reached a shared verdict that HU910, HU308, and JWH133 are the most selective choices for studying CB2 in biology and disease. The same careful profiling approach, they suggest, could vet probes for other drug targets.

Catalog record

CREATORSoethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N, Finlay D, MacDonald C, Chicca A, Gens MD, Stuart J, de Vries H, Mastrangelo N, Xia L, Alachouzos G, Baggelaar MP, Martella A, Mock ED, Deng H, Heitman LH, Connor M, Di Marzo V, Gertsch J, Lichtman AH, Maccarrone M, Pacher P, Glass M, van der Stelt M.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE103 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5216056

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity By Marjolein Soethoudt, Uwe Grether, Jürgen Fingerle, Travis W. Grim, Filomena Fezza, Luciano de Petrocellis, Christoph Ullmer, Benno Rothenhäusler, Camille Perret, Noortje van Gils, David Finlay, Christa MacDonald Published in: Nature Communications DOI: 10.1038/ncomms13958 ABSTRACT The cannabinoid CB2 receptor (CB2R) represents a promising therapeutic target for various forms of tissue injury and inflammatory diseases. Although numerous compounds have been developed and widely used to target CB2R, their selectivity, molecular mode of action and pharmacokinetic properties have been poorly characterized. Here we report the most extensive characterization of the molecular pharmacology of the most widely used CB2R ligands to date. In a collaborative effort between multiple academic and industry laboratories, we identify marked differences in the ability of certain agonists to activate distinct signalling pathways and to cause off-target effects. We reach a consensus that HU910, HU308 and JWH133 are the recommended selective CB2R agonists to study the role of CB2R in biological and disease processes. We believe that our unique approach would be highly suitable for the characterization of other therapeutic targets in drug discovery research. Target validation is an essential element of pharmacological research and drug discovery1. Pharmacological intervention using chemical probes provides a powerful means to assess the temporal consequences of acute modulation of protein function under both physiological and pathological conditions1. High selectivity and well-defined molecular mode of action of chemical probes are essential to translate the preclinical studies on non-human species to the patient. This type of information is, however, often lacking and reproducibility across different laboratories is sometimes difficult to obtain. There is a great interest in the development of selective type-2 cannabinoid receptor (CB2R) agonists as potential drug candidates for various pathophysiological conditions2, which include chronic and inflammatory pain34, pruritus5, diabetic neuropathy and nephropathy67, liver cirrhosis8, and protective effects after ischaemic-reperfusion injury9101112. CB2R belongs to the cannabinoid receptor family of G protein-coupled receptors, which also includes type-1 cannabinoid receptor (CB1R). Both CBRs are the biological target of Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive component in cannabis1314. CB1R and CB2R share an overall homology of 44%, but the 7-transmembrane spanning region, which contains the ligand-binding domain, exhibits 68% similarity15. CB2R is predominantly expressed on immune cells and its expression level is believed to increase in tissues upon pathological stimuli2, whereas the CB1R is highly expressed in the brain16. Both receptors couple to Gi/o proteins and modulate various intracellular signal transduction pathways, such as inhibition of cAMP-production, activation of pERK and G protein-coupled Inward Rectifying K+-channels (GIRKs) and recruitment of β-arrestin to the receptor171819. It is currently unknown which signal transduction pathways (or combinations thereof) are relevant for therapeutic purposes. In addition, some compounds may act as biased and/or protean agonists1819, and remarkable differences between rodent and human receptor orthologues have been noted, which are complicating the translation of results from preclinical animal models to human trials. Different chemical classes have been described as CBR ligands (for example, mixed CBR agonists: Δ9-THC (henceforth referred to as THC), CP55940, WIN55212-2, HU210, and the endogenous ligands 2-arachidonoyl glycerol (2-AG) and anandamide (AEA, N-arachidonoylethanolamine); CB1R antagonists: SR141716A (rimonabant), and AM251; CB2R agonists: HU308, HU910, Gp-1a, JWH015, JWH133 and AM1241; and CB2R antagonists: AM630 and SR144528; see Supplementary Information, Supplementary Fig. 1 for structures)220. These ligands are used to explore CBR biology and to obtain preclinical target validation of the CBR subtypes21. The high homology between the ligand binding domains of the two receptors and the overall higher tissue expression of CB1R pose challenges to develop selective ligands that target only CB2R. Yet, high selectivity is required to determine the exact role of each receptor in various (patho)physiological processes and to avoid CB1R-mediated (psychotropic) side effects caused by THC and other CB1R ligands. The need for highly selective CB2 ligands is exemplified by the scientific dispute whether the CB2R plays an important role in normal brain function or not. This whole avenue of research is currently being hampered by possible bias of using non-selective pharmacological, immunological and genetic tools and has delayed the development of novel CB2R-based drugs2223. Currently, most ligands are only characterized in a binding assay and/or in a limited set of functional assays using recombinant human receptors. The results are scattered among various publications and are derived from different experimental settings, which may have led to apparent contradictory results23. Conflicting results from in vivo models that employ some of the above-mentioned ligands have also been described in the literature (for a review see refs 2, 24). Often, information about potential off-targets and pharmacokinetics of ligands is also lacking19, which has complicated the comparison and interpretation of the data and led to confusion about which are the preferred ligands to be used for in vivo experiments aimed at validating the CB2 receptor as a therapeutic target. Unfortunately this situation, which has resulted in a loss of resources and unnecessary use of animals, is not unique to the CB2 receptor field. The US National Institutes of Health (NIH) shares these concerns from many scientists about the reproducibility issues in biomedical research and required action to counter this problem25. To improve target validation and to guide the selection of the best ligand for preclinical studies, a fully detailed profile of the current ‘gold standard' ligands is needed. To provide important guidance for the field and to address potential species-dependent differences, we comprehensively profiled the most widely used CB2R ligands. In several independent academic and industry laboratories we investigated receptor binding of both human and mouse CB2R, as well as multiple signal transduction pathways (GTPγS, cAMP, β-AR, pERK and GIRK). Selectivity of the ligands was determined towards a customized panel of proteins associated with cannabinoid ligand pharmacology, which includes the CB1R and the major proteins of the endocannabinoid system: N-acyl ethanolamines biosynthesizing enzyme NAPE-PLD and AEA hydrolysing enzyme FAAH; 2-AG biosynthesizing enzyme DAGL and hydrolysing enzymes MAGL, ABHD6 and ABHD12, as well as towards the putative endocannabinoid transporters; AEA and 2-AG-binding transient receptor potential (TRP)-channels (TRPV1–4, TRPM8 and TRPA1) (for a review see ref. 26). In addition, off-target activity on GPR55, a receptor that binds CBR-type ligands, and on COX-2, which oxygenates AEA and 2-AG, was also determined. Determination of the selectivity of CB2R ligands over these other proteins and processes involved in the endocannabinoid system, as well as over the TRP channels (which are involved in similar biological processes as the CBRs) is essential for the development of selective CB2R ligands and to avoid complications in the interpretation of the in vivo results obtained with these compounds. To assess which ligands are best suited for in vivo studies, all 18 compounds are profiled for their physico-chemical properties, in vitro absorption distribution metabolism and excretion (ADME) and pharmacokinetic parameters and cross-reactivity in the CEREP panel of 64 common off-targets. Commonly used non-selective ligands, including Δ9-THC and the endocannabinoids 2-AG and anandamide are also tested in vitro. All ligands are high-quality grade material, provided to each laboratory by the industry collaborator. The top three candidate CB2R agonists are further investigated at high doses in vivo to infer potential interactions with CNS CB1R. All data together results in the largest data set generated so far under the same experimental conditions for all cannabinoid

Read the complete text